The effect of Rifampicin on the safety, tolerability, pharmacokinetics and absolute bioavailability of oral and intravenous apixaban in healthy volunteers

Trial Profile

The effect of Rifampicin on the safety, tolerability, pharmacokinetics and absolute bioavailability of oral and intravenous apixaban in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Jan 2016

At a glance

  • Drugs Apixaban (Primary) ; Apixaban (Primary) ; Rifampicin
  • Indications Acute coronary syndromes; Stroke; Thromboembolism; Venous thromboembolism
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb; Pfizer
  • Most Recent Events

    • 21 Jan 2016 New trial record
    • 09 Jan 2016 Results published in the American Journal of Cardiovascular Drugs
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top